HealthyNCT06492694
Omega-3 Supplement and Health Markers
A study testing Fish oil + wild orange essential oil supplement and Fish oil supplement in people with Healthy, run by dōTERRA International at 1 site in United States.
Trial summary
The goal of this clinical trial is to learn whether fish oil-based supplements can affect gene expression and serum protein markers in healthy volunteers. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 18 to 64 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Fish oil + wild orange essential oil supplement and Fish oil supplement
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 55 participants
- Where
- 1 siteUnited States
- Study dates
- 10 Jun 2024to 3 Sep 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 64 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Males and females, 18-64 years old
- Local to Pleasant Grove, Utah, and/or willing to come to the clinical research center for study visits
- Willing to provide blood and urine samples during study visits
- Willing and able to consume study product daily for about 6 weeks
- Willing to track consumption of study product
- Willing to keep diet, exercise, sleeping, and current non-study supplement use the same throughout the study
Show all 19Show fewer
- Willing to avoid alcohol, recreational drugs, and smoking/vaping for the duration of the study (approximately 7 weeks)
- Willing to wash out of all internally-consumed essential oil and botanical products for at least 2 weeks prior to starting the study and willing to maintain the washout for the duration of the study (about 9 weeks)
- Willing to receive and respond to regular texts, emails, and/or phone calls from study staff
- No metabolic disease (BMI>35, diagnosis and treatment of hypertension, diabetes, or dyslipidemia)
- No major diseases under treatment by a doctor (Medical Reviewer's discretion)
- No pregnancy within the last 60 days or currently breastfeeding (females)
- No allergy to fish oil, olive oil, or orange essential oil
- No regular internal consumption of orange essential oil within the last 1 month (regularly is defined as dosing daily for more than 2 consecutive weeks, or dosing more than 2-3 times per week for 4 consecutive weeks)
- No regular internal consumption of omega-3 or other fish oil supplements within the last 1 month (regularly is defined as dosing daily for more than 2 consecutive weeks, or dosing more than 2-3 times per week for 4 consecutive weeks)
- No alcohol, recreational drug, or smoking/vaping use in the past 1 month
- No evidence of medical condition, significant disease or disorder, medication, or surgery within the past 12 months that may, in the judgment of the medical provider, put the participant at risk or affect study results, procedures, or outcomes
- Not currently or previously participating in any other clinical trial within the last 30 calendar days
- Signed informed consent, HIPAA Authorization, and Confidentiality Agreement
Who cannot join
- Failure to meet any of the above inclusion criteria
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of a Fish Oil-based, Essential-oil Infused Supplement on Markers of Health
The goal of this clinical trial is to learn whether fish oil-based supplements can affect gene expression and serum protein markers in healthy volunteers. The main questions it aims to answer are:
- How does daily ingestion of fish oil supplements affect gene expression, omega-3 levels, and protein markers as measured in blood?
- How does daily ingestion of fish oil supplements affect anthropometric measurements?
- How does daily ingestion of fish oil supplements affect subjective quality of life and health parameters?
- Do fish oil + wild orange essential oil supplements produce different outcomes than fish oil supplements alone?
- Is ingesting fish oil supplements daily safe, as measured by laboratory tests and adverse events?
Read more
Researchers will compare two types of fish oil supplements. One type contains fish oil and wild orange essential oil as its active ingredients. The other type contains only fish oil as its active ingredient.
Participants will:
- Be assigned one of the two types of fish oil supplements
- Take three softgels of their assigned supplement every day for about six weeks
- Attend two study visits in which they provide blood and urine samples, complete subjective health and quality of life assessments, and undergo anthropometric measurements
- Complete weekly subjective health assessments from home
Read the detailed description
This randomized, double-blind study will recruit healthy adults to compare gene expression profile, omega-3 levels, and protein markers before and after consumption of fish oil supplements for approximately six weeks. Quality of life will also be assessed using subjective surveys and questionnaires. Safety markers (liver and kidney function, hematology, urinalysis, and adverse events) will be collected.
- Conditions
- Healthy
- Being tested
- Fish oil + wild orange essential oil supplement, Fish oil supplement
- Keywords
- Fish oil, Omega-3, Gene expression, Wild orange essential oil
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fish oil + wild orange essential oil supplementDietary supplement
This supplement contains fish oil and wild orange essential oil as its active ingredients.
Fish oil supplementDietary supplement
This supplement contains fish oil as its active ingredient.
| Study group | Role | What they receive |
|---|---|---|
| Fish oil + wild orange essential oil supplement | Experimental | Participants in this arm will take three capsules of a fish oil + wild orange essential oil supplement daily for approximately six weeks. Receives: Dietary Supplement: Fish oil + wild orange essential oil supplement |
| Fish oil supplement | Active comparator | Participants in this arm will take three capsules of a fish oil essential oil supplement daily for approximately six weeks. Receives: Dietary Supplement: Fish oil supplement |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gene expression
Gene expression analysis refers to a genome-wide quantification of methylation. EPIC850k array will be used for methylation analysis. This represents approximately 900,000 gene locations. The main feature performed is a differential methylation analysis to determine what has significantly changed from one time point to another.
Measured: 6 weeks
Interleukin 6 (pg/mL)
Serum marker for inflammation
Measured: 6 weeks
High sensitivity C-reactive protein (mg/L)
Serum marker for inflammation and cardiac health
Measured: 6 weeks
Apolipoprotein B (mg/dL)
Serum marker for cardiovascular disease risk
Measured: 6 weeks
Total cholesterol (mg/dL)
Item in lipid panel for efficacy assessment
Measured: 6 weeks
Triglycerides (mg/dL)
Item in lipid panel for efficacy assessment
Measured: 6 weeks
High density lipoprotein (HDL) Cholesterol (mg/dL)
Item in lipid panel for efficacy assessment
Measured: 6 weeks
Very Low density lipoprotein (VLDL) Cholesterol (mg/dL)
Item in lipid panel for efficacy assessment
Measured: 6 weeks
Low density lipoprotein (LDL) Cholesterol (mg/dL)
Item in lipid panel for efficacy assessment
Measured: 6 weeks
Omega-3 blood levels (%)
Assessment of omega-3 fatty acid concentration in blood
Measured: 6 weeks
Secondary outcomes (41)
Albumin (g/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Blood urea nitrogen (BUN) (mg/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Creatinine (mg/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Alkaline phosphatase (U/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Alanine transaminase (ALT) (U/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Aspartate aminotransferase (AST) (U/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Calcium (mg/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Carbon Dioxide (mmol/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Chloride (mmol/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Potassium (mmol/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Sodium (mmol/L)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Total bilirubin (mg/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Total protein (g/dL)
Item in comprehensive metabolic panel for safety assessment
Measured: 6 weeks
Body mass index (BMI)
Determine whether body mass index is affected by the consumption of the study product.
Measured: 6 weeks
Blood pressure (mmHg)
Determine whether blood pressure is affected by the consumption of the study product.
Measured: 6 weeks
Heart rate (BPM)
Determine whether heart rate is affected by the consumption of the study product.
Measured: 6 weeks
White blood cells (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Red blood cells (x10E6/uL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Hemoglobin (g/dL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Hematocrit (%)
Item in complete blood count for safety assessment
Measured: 6 weeks
Mean corpuscular volume (fL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Mean corpuscular hemoglobin (pg)
Item in complete blood count for safety assessment
Measured: 6 weeks
Mean corpuscular hemoglobin concentration (g/dL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Red cell distribution width (%)
Item in complete blood count for safety assessment
Measured: 6 weeks
Platelets (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Neutrophils (%)
Item in complete blood count for safety assessment
Measured: 6 weeks
Lymphocytes (%)
Item in complete blood count for safety assessment
Measured: 6 weeks
Monocytes (%)
Item in complete blood count for safety assessment
Measured: 6 weeks
Eosinophils (%)
Item in complete blood count for safety assessment
Measured: 6 weeks
Basophils (%)
Item in complete blood count for safety assessment
Measured: 6 weeks
Neutrophils (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Lymphocytes (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Monocytes (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Basophils (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Immature granulocytes (%)
Item in complete blood count for safety assessment
Measured: 6 weeks
Immature granulocytes (Absolute) (x10E3/uL)
Item in complete blood count for safety assessment
Measured: 6 weeks
Safety/tolerability
This study will monitor the occurrence and frequency of adverse events and safety, both through participant report and blood chemistry/hematology analyses.
Measured: 6 weeks
Generalized Anxiety Disorder-7 (GAD-7) scale
Self-reported scale for the measurement of anxiety severity
Measured: 6 weeks
Patient Health Questionnaire (PHQ-8) scale
Self-reported scale for the measurement of depression severity
Measured: 6 weeks
Leeds Sleep Evaluation Questionnaire (LSEQ) scale
Self-reported scale for the measurement of sleep quality
Measured: 6 weeks
Short Form-20 (SF-20) scale
Self-reported scale for assessment of subjective quality of life
Measured: 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2024
- Study start10 Jun 2024
- Primary completion28 Aug 2024
- Study completion3 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 55 participants (actual)
Sponsor and investigators
- Lead sponsor
- dōTERRA International
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Nicole Stevens, PhD, Principal investigator, doTERRA International
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06492694
- Sponsor's protocol ID
- DO-124023-OWO
- Status last verified
- Jan 2025
- First submitted
- 1 Jul 2024
- Last updated
- 8 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Fish Oil-based, Essential-oil Infused Supplement on Markers of Health
- ClinicalTrials.gov ID
- NCT06492694
- Acronym / sponsor ID
- DO-124023-OWO
- Conditions
- Healthy
- Keywords
- Fish oil, Omega-3, Gene expression, Wild orange essential oil
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 55 participants (actual)
- Lead sponsor
- dōTERRA InternationalIndustry (pharma, biotech, devices)
- Study start
- 10 Jun 2024 (actual)
- Primary completion
- 28 Aug 2024 (actual)
- Study completion
- 3 Sep 2024 (actual)
- First posted
- 9 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn whether fish oil-based supplements can affect gene expression and serum protein markers in healthy volunteers. The main questions it aims to answer are:
- How does daily ingestion of fish oil supplements affect gene expression, omega-3 levels, and protein markers as measured in blood?
- How does daily ingestion of fish oil supplements affect anthropometric measurements?
- How does daily ingestion of fish oil supplements affect subjective quality of life and health parameters?
- Do fish oil + wild orange essential oil supplements produce different outcomes than fish oil supplements alone?
- Is ingesting fish oil supplements daily safe, as measured by laboratory tests and adverse events?
Researchers will compare two types of fish oil supplements. One type contains fish oil and wild orange essential oil as its active ingredients. The other type contains only fish oil as its active ingredient.
Participants will:
- Be assigned one of the two types of fish oil supplements
- Take three softgels of their assigned supplement every day for about six weeks
- Attend two study visits in which they provide blood and urine samples, complete subjective health and quality of life assessments, and undergo anthropometric measurements
- Complete weekly subjective health assessments from home
Detailed description
This randomized, double-blind study will recruit healthy adults to compare gene expression profile, omega-3 levels, and protein markers before and after consumption of fish oil supplements for approximately six weeks. Quality of life will also be assessed using subjective surveys and questionnaires. Safety markers (liver and kidney function, hematology, urinalysis, and adverse events) will be collected.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fish oil + wild orange essential oil supplement | Experimental | Dietary Supplement: Fish oil + wild orange essential oil supplementParticipants in this arm will take three capsules of a fish oil + wild orange essential oil supplement daily for approximately six weeks. |
| Fish oil supplement | Active comparator | Dietary Supplement: Fish oil supplementParticipants in this arm will take three capsules of a fish oil essential oil supplement daily for approximately six weeks. |
Who may qualify
- Ages
- 18 to 64 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (19 listed)
- Males and females, 18-64 years old
Key exclusion criteria (1 listed)
- Failure to meet any of the above inclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fish oil + wild orange essential oil supplementThis supplement contains fish oil and wild orange essential oil as its active ingredients. | Dietary supplement | Fish oil + wild orange essential oil supplement |
| Fish oil supplementThis supplement contains fish oil as its active ingredient. | Dietary supplement | Fish oil supplement |
Primary outcome
Gene expression
Time frame: 6 weeks
Gene expression analysis refers to a genome-wide quantification of methylation. EPIC850k array will be used for methylation analysis. This represents approximately 900,000 gene locations. The main feature performed is a differential methylation analysis to determine what has significantly changed from one time point to another.
Interleukin 6 (pg/mL)
Time frame: 6 weeks
Serum marker for inflammation
High sensitivity C-reactive protein (mg/L)
Time frame: 6 weeks
Serum marker for inflammation and cardiac health
Apolipoprotein B (mg/dL)
Time frame: 6 weeks
Serum marker for cardiovascular disease risk
Total cholesterol (mg/dL)
Time frame: 6 weeks
Item in lipid panel for efficacy assessment
Triglycerides (mg/dL)
Time frame: 6 weeks
Item in lipid panel for efficacy assessment
High density lipoprotein (HDL) Cholesterol (mg/dL)
Time frame: 6 weeks
Item in lipid panel for efficacy assessment
Very Low density lipoprotein (VLDL) Cholesterol (mg/dL)
Time frame: 6 weeks
Item in lipid panel for efficacy assessment
Low density lipoprotein (LDL) Cholesterol (mg/dL)
Time frame: 6 weeks
Item in lipid panel for efficacy assessment
Omega-3 blood levels (%)
Time frame: 6 weeks
Assessment of omega-3 fatty acid concentration in blood
41 secondary outcomes
Albumin (g/dL)
Time frame: 6 weeks
Blood urea nitrogen (BUN) (mg/dL)
Time frame: 6 weeks
Creatinine (mg/dL)
Time frame: 6 weeks
Alkaline phosphatase (U/L)
Time frame: 6 weeks
Alanine transaminase (ALT) (U/L)
Time frame: 6 weeks
Aspartate aminotransferase (AST) (U/L)
Time frame: 6 weeks
Calcium (mg/dL)
Time frame: 6 weeks
Carbon Dioxide (mmol/L)
Time frame: 6 weeks
Chloride (mmol/L)
Time frame: 6 weeks
Potassium (mmol/L)
Time frame: 6 weeks
Sodium (mmol/L)
Time frame: 6 weeks
Total bilirubin (mg/dL)
Time frame: 6 weeks
Total protein (g/dL)
Time frame: 6 weeks
Body mass index (BMI)
Time frame: 6 weeks
Blood pressure (mmHg)
Time frame: 6 weeks
Heart rate (BPM)
Time frame: 6 weeks
White blood cells (x10E3/uL)
Time frame: 6 weeks
Red blood cells (x10E6/uL)
Time frame: 6 weeks
Hemoglobin (g/dL)
Time frame: 6 weeks
Hematocrit (%)
Time frame: 6 weeks
Mean corpuscular volume (fL)
Time frame: 6 weeks
Mean corpuscular hemoglobin (pg)
Time frame: 6 weeks
Mean corpuscular hemoglobin concentration (g/dL)
Time frame: 6 weeks
Red cell distribution width (%)
Time frame: 6 weeks
Platelets (x10E3/uL)
Time frame: 6 weeks
Neutrophils (%)
Time frame: 6 weeks
Lymphocytes (%)
Time frame: 6 weeks
Monocytes (%)
Time frame: 6 weeks
Eosinophils (%)
Time frame: 6 weeks
Basophils (%)
Time frame: 6 weeks
Neutrophils (Absolute) (x10E3/uL)
Time frame: 6 weeks
Lymphocytes (Absolute) (x10E3/uL)
Time frame: 6 weeks
Monocytes (Absolute) (x10E3/uL)
Time frame: 6 weeks
Basophils (Absolute) (x10E3/uL)
Time frame: 6 weeks
Immature granulocytes (%)
Time frame: 6 weeks
Immature granulocytes (Absolute) (x10E3/uL)
Time frame: 6 weeks
Safety/tolerability
Time frame: 6 weeks
Generalized Anxiety Disorder-7 (GAD-7) scale
Time frame: 6 weeks
Patient Health Questionnaire (PHQ-8) scale
Time frame: 6 weeks
Leeds Sleep Evaluation Questionnaire (LSEQ) scale
Time frame: 6 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jan 2025.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nicole Stevens, PhD principal investigator
doTERRA International
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Fish oil + wild orange essential oil supplement and Fish oil supplement in people with Healthy, run by dōTERRA International at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gene expression (time frame: 6 weeks). The study lists 10 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jan 2025.